Skip to main content

Advertisement

Table 3 Summary of clinicopathological data from cats participating in the intravenous allogeneic cryopreserved mesenchymal stem cell (MSC) studies

From: Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: results of three sequential pilot studies

Study Stage Creatinine (mg/dl) Blood urea nitrogen (mg/dl) Phosphorus (mg/dl) Potassium (meq/l) Packed cell volume (%) Urine protein-to-creatinine (UPC) ratio Urine specific gravity
Pilot study 1 Before 3.5 (2.3 to 4.3) 57 (33 to 69) 3.8 (2.6 to 4.5) 4.6 (3.8 to 5.5) 31 (29 to 36) 0.1 (0.1 to 0.2) 1.016 (1.013 to 1.022)
After 3.2 (1.9 to 3.9) 53 (36 to 58) 3.7 (3.3 to 4.5) 4.2 (3.9 to 4.7) 28 (26 to 36) 0.1 (0.1 to 0.2) 1.016 (1.013 to 1.025)
Pilot study 2 Before 2.6 (1.9 to 3.7) 42 (34 to 61) 4.0 (3.6 to 4.2) 4.6 (3.7 to 5.1) 31 (27 to 35) 0.1 (0.1 to 0.2) 1.016 (1.015 to 1.030)
After 2.3 (1.8 to 3.9) 37 (30 to 64) 4.7 (2.4 to 6.7) 4.6 (3.7 to 5.0) 29 (27 to 34) 0.1 (0.1 to 0.3) 1.017 (1.013 to 1.036)
Pilot study 3 Before 2.3 (1.7 to 3.1) 49 (34 to 53) 4.2 (3.6 to 4.9) 4.7 (3.9 to 5.0) 34 (25 to 37) 0.1 (0.1 to 0.4) 1.017 (1.013 to 1.037)
  After 2.5 (1.9 to 2.8) 42 (36 to 53) 3.8 (3.7 to 3.9) 4.7 (4.1 to 5.0) 33 (28 to 34) 0.1 (0.1 to 0.4) 1.019 (1.013 to 1.029)
  1. No significant changes in clinicopathological parameters were seen as a result of repeated MSC administration in any pilot group.